A study led by investigators at the University of Alabama at Birmingham and Nationwide Children’s Hospital has provided additional evidence of the efficacy of virotherapy for glioblastoma.
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.
